Braveheart Bio is preparing to advance to Phase 3 testing in obstructive hypertrophic cardiomyopathy, or oHCM. The startup says its small molecule could have safety advantages over Camzyos, a Bristol Myers Squibb capsule projected to become a blockbuster seller in this indication.
The post Braveheart Bio Bags $185M for Drug That Could Rival a Bristol Myers Squibb Cardio Med appeared first on MedCity News.
